FDA Seeks Updates on U.S. Food Exporters' Contact Lists
Published Date: 8/22/2025
Notice
Summary
The FDA wants to keep an updated list of U.S. businesses interested in exporting human food products they regulate. This helps the FDA stay in the loop and support safe food exports. If you’re a food business, get ready to share some info soon—this won’t cost you much time or money but keeps things running smoothly!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
FDA Exporter Interest List for Food Businesses
The FDA will establish and maintain an updated list of U.S. businesses that are interested in exporting human food products the agency regulates. Businesses will be asked to submit contact and interest information as part of an information collection the FDA has submitted to the Office of Management and Budget for review under the Paperwork Reduction Act of 1995. The agency says this information collection won’t cost businesses much time or money.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12855 — Sterigenics U.S., LLC; Filing of Food Additive Petition
Sterigenics U.S., LLC wants to get approval to use a new food additive. This affects food makers and consumers by potentially changing how certain foods are treated or preserved. No big costs or deadlines are mentioned yet, but keep an eye out for updates as the process moves forward!
2026-12621 — Expedited Investigational New Drug Pilot Program; Request for Information
The FDA wants to speed up how fast new drugs get tested on people by creating a special pilot program. This program will team up trusted research groups with drug makers to review early study plans faster, while keeping safety top priority. If you’re involved in drug research or healthcare, now’s your chance to share ideas before July 22, 2026!
2026-12679 — International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Bovines; Guidance for Industry; Availability
The FDA just released new guidance to help companies test worm-killing medicines for cows. This makes it easier for drug makers worldwide to prove their products work, speeding up approvals and keeping cattle healthy. Farmers, vets, and drug companies should watch for these changes starting now—no extra costs, just clearer rules!
2026-12622 — Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products; Revised Draft Guidance for Industry; Availability
The FDA just released a new draft guide to help drug makers prove their medicines really work, using smarter and faster science. This update affects companies developing human drugs and biological products, aiming to save time and money by allowing strong evidence from just one good clinical study plus extra proof. Comments on this draft are open until September 22, 2026, so industry folks have a chance to weigh in before it becomes final.
2026-12681 — International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations for Caprines; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers prove their worm-killing medicines work well in goats. This makes it easier for companies worldwide to get their products approved by following the same rules. Goat farmers, vets, and drug companies should watch for these updates starting June 24, 2026, which could speed up getting effective treatments to animals without extra costs.
2026-12620 — Master Protocols for Drug and Biological Product Development; Draft Guidance for Industry; Availability
The FDA just dropped a fresh draft guidance to help drug and biological product makers run smarter, faster clinical trials using master protocols. This update affects companies developing new medicines by clarifying how to design and submit these trials for approval. If you’re in the game, get your comments in by August 24, 2026, or risk missing out on shaping the final rules—and maybe saving time and money down the road!
Previous / Next Documents
Previous: 2025-16074 — Performance Review Board, Senior Executive Service (SES)
The government is sharing who’s on NASA’s Performance Review Board for top senior executives. This board helps review how well these leaders are doing their jobs. It’s a routine update with no new changes or money involved, just keeping things official and transparent.
Next: 2025-16076 — Notice of Determinations; Culturally Significant Objects Being Imported for Exhibition-Determinations: “Lines of Resolution: Drawing at the Advent of Television and Video” Exhibition
The government has decided that some special art pieces coming from other countries for the “Lines of Resolution” exhibition in Houston are super important to culture. These artworks will be shown temporarily in the U.S. because it benefits everyone. This means the exhibition can go ahead smoothly, sharing cool history and creativity with the public.